IDEXX Laboratories Announces First Quart...(s $3285 $2...),Health

Date:4/24/2009

s $3,285 $24,768 Net effect of exchange rate changes (1,603) 2,689 Net increase (decrease) in cash and cash equivalents 7,427 (140) Cash and cash equivalents, beginning of period 78,868 60,360 Cash and cash equivalents, end of period $86,295 $60,220 IDEXX Laboratories, Inc. and Subsidiaries Free Cash Flow Amounts in thousands (Unaudited) Three Months Ended March 31, March 31, 2009 2008 Free Cash Flow: Net cash provided (used) by operating activities $12,624 $(2,789) Financing cash flows attributable to tax benefits from exercise of stock options 161 2,384 Purchase of fixed assets (9,114) (17,049) Acquisition of equipment leased to customers (188) (226) Free cash flow $3,483 $(17,680) Free cash flow indicates the cash generated from operations and tax benefits attributable to stock option exercises, reduced by investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. IDEXX Laboratories, Inc. and Subsidiaries Common St
'/>"/>

SOURCE IDEXX Laboratories, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
3. IDEXX Laboratories Announces Fourth Quarter Results
4. IDEXX Laboratories Announces Increase in Share Repurchase Program
5. IDEXX Laboratories to Release 2008 First Quarter Financial Results
6. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
9. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)